Destination LVAD National Coverage Determination Referred To MCAC
This article was originally published in The Gray Sheet
Executive Summary
Thoratec anticipates Medicare coverage of the HeartMate VE left-ventricular assist device as "destination therapy" in 2003, despite CMS' Oct. 30 announcement that it has referred the procedure to the Medicare Coverage Advisory Committee
You may also be interested in...
Thoratec Hopes MCAC Will Follow Blues’ Lead To Cover Destination LVADs
Thoratec expects to meet with the Medicare Coverage Advisory Committee in early March to discuss expanding coverage of the HeartMate SNAP-VE left-ventricular assist device to include destination therapy for end-stage heart failure patients
Thoratec Hopes MCAC Will Follow Blues’ Lead To Cover Destination LVADs
Thoratec expects to meet with the Medicare Coverage Advisory Committee in early March to discuss expanding coverage of the HeartMate SNAP-VE left-ventricular assist device to include destination therapy for end-stage heart failure patients
WorldHeart Will Learn Fate Of Novacor As Destination Therapy Within 90 Days
WorldHeart may ask FDA's Medical Device Dispute Resolution Panel to re-evaluate the firm's PMA supplement for the Novacor left-ventricular assist device as a destination therapy, according to CEO Rod Bryden